Global 13-Valent Pneumococcal Conjugate Vaccine Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global 13-Valent Pneumococcal Conjugate Vaccine market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
The Global Info Research report includes an overview of the development of the 13-Valent Pneumococcal Conjugate Vaccine industry chain, the market status of Hospital (Vials, Pre-filled), Clinic (Vials, Pre-filled), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of 13-Valent Pneumococcal Conjugate Vaccine.
Regionally, the report analyzes the 13-Valent Pneumococcal Conjugate Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global 13-Valent Pneumococcal Conjugate Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the 13-Valent Pneumococcal Conjugate Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the 13-Valent Pneumococcal Conjugate Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Vials, Pre-filled).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the 13-Valent Pneumococcal Conjugate Vaccine market.
Regional Analysis: The report involves examining the 13-Valent Pneumococcal Conjugate Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the 13-Valent Pneumococcal Conjugate Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to 13-Valent Pneumococcal Conjugate Vaccine:
Company Analysis: Report covers individual 13-Valent Pneumococcal Conjugate Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards 13-Valent Pneumococcal Conjugate Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to 13-Valent Pneumococcal Conjugate Vaccine. It assesses the current state, advancements, and potential future developments in 13-Valent Pneumococcal Conjugate Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the 13-Valent Pneumococcal Conjugate Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
13-Valent Pneumococcal Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Chapter 1, to describe 13-Valent Pneumococcal Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of 13-Valent Pneumococcal Conjugate Vaccine, with price, sales, revenue and global market share of 13-Valent Pneumococcal Conjugate Vaccine from 2018 to 2023.
Chapter 3, the 13-Valent Pneumococcal Conjugate Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 13-Valent Pneumococcal Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and 13-Valent Pneumococcal Conjugate Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of 13-Valent Pneumococcal Conjugate Vaccine.
Chapter 14 and 15, to describe 13-Valent Pneumococcal Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.
The Global Info Research report includes an overview of the development of the 13-Valent Pneumococcal Conjugate Vaccine industry chain, the market status of Hospital (Vials, Pre-filled), Clinic (Vials, Pre-filled), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of 13-Valent Pneumococcal Conjugate Vaccine.
Regionally, the report analyzes the 13-Valent Pneumococcal Conjugate Vaccine markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global 13-Valent Pneumococcal Conjugate Vaccine market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the 13-Valent Pneumococcal Conjugate Vaccine market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the 13-Valent Pneumococcal Conjugate Vaccine industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the sales quantity (K Units), revenue generated, and market share of different by Type (e.g., Vials, Pre-filled).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the 13-Valent Pneumococcal Conjugate Vaccine market.
Regional Analysis: The report involves examining the 13-Valent Pneumococcal Conjugate Vaccine market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the 13-Valent Pneumococcal Conjugate Vaccine market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to 13-Valent Pneumococcal Conjugate Vaccine:
Company Analysis: Report covers individual 13-Valent Pneumococcal Conjugate Vaccine manufacturers, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards 13-Valent Pneumococcal Conjugate Vaccine This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Hospital, Clinic).
Technology Analysis: Report covers specific technologies relevant to 13-Valent Pneumococcal Conjugate Vaccine. It assesses the current state, advancements, and potential future developments in 13-Valent Pneumococcal Conjugate Vaccine areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the 13-Valent Pneumococcal Conjugate Vaccine market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
13-Valent Pneumococcal Conjugate Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
- Vials
- Pre-filled
- Hospital
- Clinic
- CDC
- Pfizer
- Kangtai
- Walvax Biotechnology
- North America (United States, Canada and Mexico)
- Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
- South America (Brazil, Argentina, Colombia, and Rest of South America)
- Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
Chapter 1, to describe 13-Valent Pneumococcal Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of 13-Valent Pneumococcal Conjugate Vaccine, with price, sales, revenue and global market share of 13-Valent Pneumococcal Conjugate Vaccine from 2018 to 2023.
Chapter 3, the 13-Valent Pneumococcal Conjugate Vaccine competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the 13-Valent Pneumococcal Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and 13-Valent Pneumococcal Conjugate Vaccine market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of 13-Valent Pneumococcal Conjugate Vaccine.
Chapter 14 and 15, to describe 13-Valent Pneumococcal Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of 13-Valent Pneumococcal Conjugate Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Vials
1.3.3 Pre-filled
1.4 Market Analysis by Application
1.4.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 CDC
1.5 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size & Forecast
1.5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029)
1.5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.1.4 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Kangtai
2.2.1 Kangtai Details
2.2.2 Kangtai Major Business
2.2.3 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.2.4 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Kangtai Recent Developments/Updates
2.3 Walvax Biotechnology
2.3.1 Walvax Biotechnology Details
2.3.2 Walvax Biotechnology Major Business
2.3.3 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.3.4 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Walvax Biotechnology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE BY MANUFACTURER
3.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
3.5 13-Valent Pneumococcal Conjugate Vaccine Market: Overall Company Footprint Analysis
3.5.1 13-Valent Pneumococcal Conjugate Vaccine Market: Region Footprint
3.5.2 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
3.5.3 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
4.1.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2029)
4.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.5 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2029)
5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
6.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2029)
6.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
7.2 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
7.3 North America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
7.3.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
8.3.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
9.3.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
10.2 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
10.3 South America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
10.3.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
11.3.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
12.2 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
12.3 13-Valent Pneumococcal Conjugate Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of 13-Valent Pneumococcal Conjugate Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of 13-Valent Pneumococcal Conjugate Vaccine
13.3 13-Valent Pneumococcal Conjugate Vaccine Production Process
13.4 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
14.3 13-Valent Pneumococcal Conjugate Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
1.1 Product Overview and Scope of 13-Valent Pneumococcal Conjugate Vaccine
1.2 Market Estimation Caveats and Base Year
1.3 Market Analysis by Type
1.3.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type: 2018 Versus 2022 Versus 2029
1.3.2 Vials
1.3.3 Pre-filled
1.4 Market Analysis by Application
1.4.1 Overview: Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application: 2018 Versus 2022 Versus 2029
1.4.2 Hospital
1.4.3 Clinic
1.4.4 CDC
1.5 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size & Forecast
1.5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018 & 2022 & 2029)
1.5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029)
1.5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2018-2029)
2 MANUFACTURERS PROFILES
2.1 Pfizer
2.1.1 Pfizer Details
2.1.2 Pfizer Major Business
2.1.3 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.1.4 Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 Pfizer Recent Developments/Updates
2.2 Kangtai
2.2.1 Kangtai Details
2.2.2 Kangtai Major Business
2.2.3 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.2.4 Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Kangtai Recent Developments/Updates
2.3 Walvax Biotechnology
2.3.1 Walvax Biotechnology Details
2.3.2 Walvax Biotechnology Major Business
2.3.3 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
2.3.4 Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Walvax Biotechnology Recent Developments/Updates
3 COMPETITIVE ENVIRONMENT: 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE BY MANUFACTURER
3.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023)
3.2 Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023)
3.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023)
3.4 Market Share Analysis (2022)
3.4.1 Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2022
3.4.2 Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
3.4.2 Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer Market Share in 2022
3.5 13-Valent Pneumococcal Conjugate Vaccine Market: Overall Company Footprint Analysis
3.5.1 13-Valent Pneumococcal Conjugate Vaccine Market: Region Footprint
3.5.2 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
3.5.3 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
3.6 New Market Entrants and Barriers to Market Entry
3.7 Mergers, Acquisition, Agreements, and Collaborations
4 CONSUMPTION ANALYSIS BY REGION
4.1 Global 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
4.1.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
4.1.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
4.1.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2029)
4.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.4 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.5 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
4.6 Middle East and Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029)
5 MARKET SEGMENT BY TYPE
5.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
5.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2029)
5.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029)
6 MARKET SEGMENT BY APPLICATION
6.1 Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
6.2 Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2029)
6.3 Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029)
7 NORTH AMERICA
7.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
7.2 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
7.3 North America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
7.3.1 North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
7.3.2 North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
7.3.3 United States Market Size and Forecast (2018-2029)
7.3.4 Canada Market Size and Forecast (2018-2029)
7.3.5 Mexico Market Size and Forecast (2018-2029)
8 EUROPE
8.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
8.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
8.3 Europe 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
8.3.1 Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
8.3.2 Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
8.3.3 Germany Market Size and Forecast (2018-2029)
8.3.4 France Market Size and Forecast (2018-2029)
8.3.5 United Kingdom Market Size and Forecast (2018-2029)
8.3.6 Russia Market Size and Forecast (2018-2029)
8.3.7 Italy Market Size and Forecast (2018-2029)
9 ASIA-PACIFIC
9.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
9.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
9.3 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Market Size by Region
9.3.1 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2029)
9.3.2 Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2029)
9.3.3 China Market Size and Forecast (2018-2029)
9.3.4 Japan Market Size and Forecast (2018-2029)
9.3.5 Korea Market Size and Forecast (2018-2029)
9.3.6 India Market Size and Forecast (2018-2029)
9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
9.3.8 Australia Market Size and Forecast (2018-2029)
10 SOUTH AMERICA
10.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
10.2 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
10.3 South America 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
10.3.1 South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
10.3.2 South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
10.3.3 Brazil Market Size and Forecast (2018-2029)
10.3.4 Argentina Market Size and Forecast (2018-2029)
11 MIDDLE EAST & AFRICA
11.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2029)
11.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2029)
11.3 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Market Size by Country
11.3.1 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2029)
11.3.2 Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2029)
11.3.3 Turkey Market Size and Forecast (2018-2029)
11.3.4 Egypt Market Size and Forecast (2018-2029)
11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
11.3.6 South Africa Market Size and Forecast (2018-2029)
12 MARKET DYNAMICS
12.1 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
12.2 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
12.3 13-Valent Pneumococcal Conjugate Vaccine Trends Analysis
12.4 Porters Five Forces Analysis
12.4.1 Threat of New Entrants
12.4.2 Bargaining Power of Suppliers
12.4.3 Bargaining Power of Buyers
12.4.4 Threat of Substitutes
12.4.5 Competitive Rivalry
13 RAW MATERIAL AND INDUSTRY CHAIN
13.1 Raw Material of 13-Valent Pneumococcal Conjugate Vaccine and Key Manufacturers
13.2 Manufacturing Costs Percentage of 13-Valent Pneumococcal Conjugate Vaccine
13.3 13-Valent Pneumococcal Conjugate Vaccine Production Process
13.4 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain
14 SHIPMENTS BY DISTRIBUTION CHANNEL
14.1 Sales Channel
14.1.1 Direct to End-User
14.1.2 Distributors
14.2 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
14.3 13-Valent Pneumococcal Conjugate Vaccine Typical Customers
15 RESEARCH FINDINGS AND CONCLUSION
16 APPENDIX
16.1 Methodology
16.2 Research Process and Data Source
16.3 Disclaimer
LIST OF TABLES
Table 1. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 6. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Recent Developments/Updates
Table 8. Kangtai Basic Information, Manufacturing Base and Competitors
Table 9. Kangtai Major Business
Table 10. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 11. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Kangtai Recent Developments/Updates
Table 13. Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
Table 14. Walvax Biotechnology Major Business
Table 15. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 16. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Walvax Biotechnology Recent Developments/Updates
Table 18. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 19. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 20. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Market Position of Manufacturers in 13-Valent Pneumococcal Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 22. Head Office and 13-Valent Pneumococcal Conjugate Vaccine Production Site of Key Manufacturer
Table 23. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
Table 24. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
Table 25. 13-Valent Pneumococcal Conjugate Vaccine New Market Entrants and Barriers to Market Entry
Table 26. 13-Valent Pneumococcal Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 28. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 29. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 30. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 31. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 33. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 34. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 35. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 36. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 37. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 38. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 39. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 40. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 41. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 42. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 43. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 44. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 45. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 46. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 47. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 48. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 49. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 50. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 51. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 52. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 53. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 54. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 55. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 56. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 57. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 58. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 59. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 62. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 63. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 64. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 65. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 66. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 67. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 68. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 69. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 70. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 71. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 72. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 73. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 74. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 75. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 76. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 77. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 78. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 79. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 80. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 81. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 82. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 83. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 84. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 85. 13-Valent Pneumococcal Conjugate Vaccine Raw Material
Table 86. Key Manufacturers of 13-Valent Pneumococcal Conjugate Vaccine Raw Materials
Table 87. 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
Table 88. 13-Valent Pneumococcal Conjugate Vaccine Typical Customers
Table 1. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
Table 4. Pfizer Major Business
Table 5. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 6. Pfizer 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 7. Pfizer Recent Developments/Updates
Table 8. Kangtai Basic Information, Manufacturing Base and Competitors
Table 9. Kangtai Major Business
Table 10. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 11. Kangtai 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 12. Kangtai Recent Developments/Updates
Table 13. Walvax Biotechnology Basic Information, Manufacturing Base and Competitors
Table 14. Walvax Biotechnology Major Business
Table 15. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Product and Services
Table 16. Walvax Biotechnology 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 17. Walvax Biotechnology Recent Developments/Updates
Table 18. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Manufacturer (2018-2023) & (K Units)
Table 19. Global 13-Valent Pneumococcal Conjugate Vaccine Revenue by Manufacturer (2018-2023) & (USD Million)
Table 20. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Manufacturer (2018-2023) & (US$/Unit)
Table 21. Market Position of Manufacturers in 13-Valent Pneumococcal Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Consumption Value in 2022
Table 22. Head Office and 13-Valent Pneumococcal Conjugate Vaccine Production Site of Key Manufacturer
Table 23. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Type Footprint
Table 24. 13-Valent Pneumococcal Conjugate Vaccine Market: Company Product Application Footprint
Table 25. 13-Valent Pneumococcal Conjugate Vaccine New Market Entrants and Barriers to Market Entry
Table 26. 13-Valent Pneumococcal Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
Table 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 28. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 29. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 30. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 31. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2018-2023) & (US$/Unit)
Table 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Region (2024-2029) & (US$/Unit)
Table 33. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 34. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 35. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2018-2023) & (USD Million)
Table 36. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type (2024-2029) & (USD Million)
Table 37. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2023) & (US$/Unit)
Table 38. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2024-2029) & (US$/Unit)
Table 39. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 40. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 41. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2018-2023) & (USD Million)
Table 42. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application (2024-2029) & (USD Million)
Table 43. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2023) & (US$/Unit)
Table 44. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2024-2029) & (US$/Unit)
Table 45. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 46. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 47. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 48. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 49. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 50. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 51. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 52. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 53. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 54. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 55. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 56. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 57. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 58. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 59. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 60. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 61. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 62. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 63. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 64. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 65. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 66. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 67. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 68. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 69. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 70. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 71. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 72. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 73. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2018-2023) & (K Units)
Table 74. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Country (2024-2029) & (K Units)
Table 75. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2018-2023) & (USD Million)
Table 76. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Country (2024-2029) & (USD Million)
Table 77. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2018-2023) & (K Units)
Table 78. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Type (2024-2029) & (K Units)
Table 79. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2018-2023) & (K Units)
Table 80. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Application (2024-2029) & (K Units)
Table 81. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2018-2023) & (K Units)
Table 82. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity by Region (2024-2029) & (K Units)
Table 83. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2018-2023) & (USD Million)
Table 84. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Region (2024-2029) & (USD Million)
Table 85. 13-Valent Pneumococcal Conjugate Vaccine Raw Material
Table 86. Key Manufacturers of 13-Valent Pneumococcal Conjugate Vaccine Raw Materials
Table 87. 13-Valent Pneumococcal Conjugate Vaccine Typical Distributors
Table 88. 13-Valent Pneumococcal Conjugate Vaccine Typical Customers
LIST OF FIGURES
Figure 1. 13-Valent Pneumococcal Conjugate Vaccine Picture
Figure 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Vials Examples
Figure 5. Pre-filled Examples
Figure 6. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. CDC Examples
Figure 11. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 14. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 15. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 22. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 29. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 37. United States 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 53. China 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
Figure 74. 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
Figure 75. 13-Valent Pneumococcal Conjugate Vaccine Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Conjugate Vaccine in 2022
Figure 78. Manufacturing Process Analysis of 13-Valent Pneumococcal Conjugate Vaccine
Figure 79. 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
Figure 1. 13-Valent Pneumococcal Conjugate Vaccine Picture
Figure 2. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type in 2022
Figure 4. Vials Examples
Figure 5. Pre-filled Examples
Figure 6. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Figure 7. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application in 2022
Figure 8. Hospital Examples
Figure 9. Clinic Examples
Figure 10. CDC Examples
Figure 11. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 12. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 13. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity (2018-2029) & (K Units)
Figure 14. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price (2018-2029) & (US$/Unit)
Figure 15. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2022
Figure 16. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Manufacturer in 2022
Figure 17. Producer Shipments of 13-Valent Pneumococcal Conjugate Vaccine by Manufacturer Sales Quantity ($MM) and Market Share (%): 2021
Figure 18. Top 3 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 19. Top 6 13-Valent Pneumococcal Conjugate Vaccine Manufacturer (Consumption Value) Market Share in 2022
Figure 20. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 21. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 22. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 23. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 24. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 25. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 26. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value (2018-2029) & (USD Million)
Figure 27. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 28. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Type (2018-2029)
Figure 29. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Type (2018-2029) & (US$/Unit)
Figure 30. Global 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 31. Global 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Application (2018-2029)
Figure 32. Global 13-Valent Pneumococcal Conjugate Vaccine Average Price by Application (2018-2029) & (US$/Unit)
Figure 33. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 34. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 35. North America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 36. North America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 37. United States 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 38. Canada 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 39. Mexico 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 40. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 41. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 42. Europe 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 43. Europe 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 44. Germany 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 45. France 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 46. United Kingdom 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 47. Russia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 48. Italy 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 49. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 50. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 51. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 52. Asia-Pacific 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 53. China 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 54. Japan 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 55. Korea 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 56. India 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 57. Southeast Asia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 58. Australia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 59. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 60. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 61. South America 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Country (2018-2029)
Figure 62. South America 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Country (2018-2029)
Figure 63. Brazil 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 64. Argentina 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 65. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Type (2018-2029)
Figure 66. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Application (2018-2029)
Figure 67. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Sales Quantity Market Share by Region (2018-2029)
Figure 68. Middle East & Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value Market Share by Region (2018-2029)
Figure 69. Turkey 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 70. Egypt 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 71. Saudi Arabia 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 72. South Africa 13-Valent Pneumococcal Conjugate Vaccine Consumption Value and Growth Rate (2018-2029) & (USD Million)
Figure 73. 13-Valent Pneumococcal Conjugate Vaccine Market Drivers
Figure 74. 13-Valent Pneumococcal Conjugate Vaccine Market Restraints
Figure 75. 13-Valent Pneumococcal Conjugate Vaccine Market Trends
Figure 76. Porters Five Forces Analysis
Figure 77. Manufacturing Cost Structure Analysis of 13-Valent Pneumococcal Conjugate Vaccine in 2022
Figure 78. Manufacturing Process Analysis of 13-Valent Pneumococcal Conjugate Vaccine
Figure 79. 13-Valent Pneumococcal Conjugate Vaccine Industrial Chain
Figure 80. Sales Quantity Channel: Direct to End-User vs Distributors
Figure 81. Direct Channel Pros & Cons
Figure 82. Indirect Channel Pros & Cons
Figure 83. Methodology
Figure 84. Research Process and Data Source
